Academic Journal
P0890 Real-World Outcomes of Upadacitinib in Crohn’s Disease: Insights from ENEIDA database
| العنوان: | P0890 Real-World Outcomes of Upadacitinib in Crohn’s Disease: Insights from ENEIDA database |
|---|---|
| المؤلفون: | Iborra, M, Botella, B, Martín-Arranz, M D, Ceballos, D, Martínez-Pascual, C, Ripoll, P, Varela, P, Moreta, M, Montserrat, A, González-Lama, Y, Rodríguez-González, E, Vicuña, M, Gisbert, J P, Ordás, I, Argüelles-Arias, F, Tosca, J, Vicente, R, Sierra, M, Rodríguez-Lago, I, Martín-Rodríguez, D, Paredes, J M, Sicilia, B, García de la Filia, I, Jiménez, N, Barreiro de Acosta, M, Betoré, E, Ferrer, I, García-Allés, L, Huguet, J M, Castellet, S, García, M J, Gutiérrez, A, Ponferrada, Á, Ramos, L, Calafat, M, Domènech, E, Nos, P |
| المصدر: | Journal of Crohn's and Colitis ; volume 19, issue Supplement_1, page i1688-i1689 ; ISSN 1873-9946 1876-4479 |
| بيانات النشر: | Oxford University Press (OUP) |
| سنة النشر: | 2025 |
| الوصف: | Background Upadacitinib (UPA) is the first oral JAK inhibitor approved for the treatment of Crohn's disease (CD). While its effectiveness and safety are well-documented in pivotal clinical trials, real-world data remain limited. Aim: To evaluate the real-world efficacy and safety of UPA in both the short and long term for CD patients. Methods A multicentre, prospective, observational study was conducted on patients receiving UPA since its approval. Epidemiological, clinical and disease-related variables, cardiovascular risk factors (CVRF) and prior treatments, were collected. Disease activity was assessed using the Harvey-Bradshaw Index (HBI), endoscopic/radiological (E/R) evaluations, C-reactive protein (CRP), and faecal calprotectin (FC) levels at baseline, 12, 24, and 52 weeks (W). Adverse events (AEs) hospitalisations, and treatment discontinuations were also recorded. Results A total of 300 CD patients were included (mean follow-up of 42 W (SD 27.4)). Of these, 26 (9%) received UPA in combination with biological therapy, 24 (8%) were treated for extraintestinal manifestations (EIM) without luminal disease, and 250 (83%) for luminal CD. Baseline characteristics are presented in Figure 1. Regarding prior advanced therapies, 15% had received one, 26% two, 29% three and 29% ≥four. At baseline, 70% of patients (210) underwent E/R evaluations, which revealed moderate or severe disease activity in 45% and 37%, respectively. Clinical remission was achieved in 62%, 65% and 67% of patients at W12, 24, 52. FC and CRP levels returned to normal (<250 μg/g and <3 mg/L respectively) in the 50%, 55% and 62%, and 60%, 64% and 65% of the patients at W12, 24 and 52, respectively. Over the follow-up period, HBI, FC, and CRP levels significantly improved (Figure 2) and 113 patients (40%) underwent E/R evaluations of which 16% and 32% showed inactive or mild disease activity, respectively. Patients receiving combination therapy showed significant improvement in HBI though decreases in CRP and FC were not ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1093/ecco-jcc/jjae190.1064 |
| الاتاحة: | https://doi.org/10.1093/ecco-jcc/jjae190.1064 https://academic.oup.com/ecco-jcc/article-pdf/19/Supplement_1/i1688/61545779/jjae190.1064.pdf |
| Rights: | https://academic.oup.com/pages/standard-publication-reuse-rights |
| رقم الانضمام: | edsbas.CE6AB494 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/ecco-jcc/jjae190.1064 |
|---|